DURECT (DRRX) Competitors $1.91 0.00 (0.00%) As of 09/11/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DRRX vs. VYGR, LYEL, TKNO, TNXP, SGMT, ACIU, ACRS, HUMA, AVTE, and OGIShould you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Voyager Therapeutics (VYGR), Lyell Immunopharma (LYEL), Alpha Teknova (TKNO), Tonix Pharmaceuticals (TNXP), Sagimet Biosciences (SGMT), AC Immune (ACIU), Aclaris Therapeutics (ACRS), Humacyte (HUMA), Aerovate Therapeutics (AVTE), and Organigram Global (OGI). These companies are all part of the "pharmaceutical products" industry. DURECT vs. Its Competitors Voyager Therapeutics Lyell Immunopharma Alpha Teknova Tonix Pharmaceuticals Sagimet Biosciences AC Immune Aclaris Therapeutics Humacyte Aerovate Therapeutics Organigram Global Voyager Therapeutics (NASDAQ:VYGR) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability. Which has stronger valuation and earnings, VYGR or DRRX? DURECT has lower revenue, but higher earnings than Voyager Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$42.58M5.45-$65M-$1.85-2.26DURECT$1.66M35.80-$8.32M-$0.10-19.10 Is VYGR or DRRX more profitable? DURECT has a net margin of -96.19% compared to Voyager Therapeutics' net margin of -253.49%. Voyager Therapeutics' return on equity of -37.65% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics-253.49% -37.65% -28.89% DURECT -96.19%-259.16%-71.78% Do institutionals & insiders hold more shares of VYGR or DRRX? 48.0% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 28.0% of DURECT shares are held by institutional investors. 6.4% of Voyager Therapeutics shares are held by company insiders. Comparatively, 3.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend VYGR or DRRX? Voyager Therapeutics presently has a consensus price target of $13.25, suggesting a potential upside of 216.92%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13DURECT 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media refer more to VYGR or DRRX? In the previous week, DURECT had 6 more articles in the media than Voyager Therapeutics. MarketBeat recorded 8 mentions for DURECT and 2 mentions for Voyager Therapeutics. Voyager Therapeutics' average media sentiment score of 1.81 beat DURECT's score of 0.71 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive DURECT 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VYGR or DRRX? Voyager Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, DURECT has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. SummaryVoyager Therapeutics beats DURECT on 11 of the 17 factors compared between the two stocks. Get DURECT News Delivered to You Automatically Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRRX vs. The Competition Export to ExcelMetricDURECTMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.31M$2.59B$5.84B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-19.1023.8575.4125.98Price / Sales35.80529.66515.81181.13Price / CashN/A171.1637.5660.44Price / Book6.595.3712.156.29Net Income-$8.32M$32.95M$3.29B$271.07M7 Day PerformanceN/A1.28%0.74%3.87%1 Month Performance0.53%5.61%5.00%5.49%1 Year Performance26.49%-1.67%62.53%25.86% DURECT Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRRXDURECT1.5227 of 5 stars$1.91flatN/AN/A$59.31M$1.66M-19.1080News CoverageOptions VolumeVYGRVoyager Therapeutics3.9427 of 5 stars$4.26+0.5%$13.25+211.0%-33.1%$235.19M$80M-2.30100Positive NewsGap UpLYELLyell Immunopharma2.9047 of 5 stars$13.03+7.2%$15.00+15.1%-47.9%$233.42M$60K-0.54270Positive NewsTKNOAlpha Teknova2.8174 of 5 stars$4.35-0.2%$10.00+129.9%+1.1%$233.33M$37.74M-10.36240Positive NewsTNXPTonix Pharmaceuticals3.2753 of 5 stars$25.29-4.7%$70.00+176.8%+82.5%$232.65M$9.83M-0.6450Gap DownSGMTSagimet Biosciences3.3354 of 5 stars$7.03-1.1%$25.67+265.1%+81.7%$231.23M$2M-3.848Positive NewsAnalyst DowngradeACIUAC Immune2.4693 of 5 stars$2.20-3.5%$10.00+354.5%-23.6%$228.94M$31.02M-3.79140Positive NewsAnalyst UpgradeACRSAclaris Therapeutics2.8303 of 5 stars$2.08-1.0%$8.71+319.0%+65.3%$227.50M$18.72M-1.52100Positive NewsGap DownHUMAHumacyte3.0003 of 5 stars$1.41-1.4%$9.75+591.5%-73.9%$226.47M$1.57M-3.13150Positive NewsAVTEAerovate TherapeuticsN/A$7.77-0.1%N/A-88.4%$225.21MN/A-2.6020Positive NewsHigh Trading VolumeOGIOrganigram Global1.1051 of 5 stars$1.64-0.6%N/A-10.8%$221.18M$117.47M32.81860 Related Companies and Tools Related Companies VYGR Competitors LYEL Competitors TKNO Competitors TNXP Competitors SGMT Competitors ACIU Competitors ACRS Competitors HUMA Competitors AVTE Competitors OGI Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRRX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRRX Stock Alerts